During the past decade, Seattle Cancer Care Alliance/University of Washington Medical Center conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 4 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Seattle Cancer Care Alliance/University of Washington Medical Center" #1 sponsor was "Seagen Inc." with 4 trials, followed by "Hoffmann-La Roche" with 2 trials sponsored, "Aadi Bioscience, Inc." with 1 trials sponsored, "Boston Scientific Corporation" with 1 trials sponsored and "Dana-Farber Cancer Institute" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Seattle Cancer Care Alliance/University of Washington Medical Center" #1 collaborator was "Millennium Pharmaceuticals, Inc." with 3 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Biocompatibles UK Ltd" with 1 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator and "GOG Foundation" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Seattle Cancer Care Alliance/University of Washington Medical Center" are "Lymphoma, Large-Cell, Anaplastic" (3 trials), "Lymphoma, Non-Hodgkin" (3 trials), "Disease, Hodgkin" (2 trials), "Cancer" (1 trials) and "Carcinomas" (1 trials). Many other conditions were trialed in "Seattle Cancer Care Alliance/University of Washington Medical Center" in a lesser frequency.

Most popular intervention types in "Seattle Cancer Care Alliance/University of Washington Medical Center" are "Drug" (9 trials), "Biological" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "brentuximab vedotin" (4 trials), "Atezolizumab" (2 trials), "Abemaciclib" (1 trials), "Bevacizumab" (1 trials) and "Cobimetinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Seattle Cancer Care Alliance/University of Washington Medical Center" are 9 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Seattle Cancer Care Alliance/University of Washington Medical Center". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Seattle Cancer Care Alliance/University of Washington Medical Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Seattle Cancer Care Alliance/University of Washington Medical Center, 4 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".